Similar articles

• Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis.

  Kapoor R, Miller DH, Jones SJ, Plant GT, Brusa A, Gass A, Hawkins CP, Page R, Wood NW, Compston DA, Moseley IF, McDonald WI. Kapoor R, et al. Neurology. 1998 Jan;50(1):230-7. doi: 10.1212/wnl.50.1.230. Neurology. 1998. PMID: 9443485 Clinical Trial.
• Recent advances in the management of optic neuritis.

  Kortvelesy S. Kortvelesy S. Hawaii Med J. 1997 Oct;56(10):281. Hawaii Med J. 1997. PMID: 9385746 Review. No abstract available.
• The Optic Neuritis Treatment Trial. Putting the results in perspective. The Optic Neuritis Study Group.

  Beck RW, Trobe JD. Beck RW, et al. J Neuroophthalmol. 1995 Sep;15(3):131-5. J Neuroophthalmol. 1995. PMID: 8574355 Clinical Trial. No abstract available.
• What we have learned from the optic neuritis treatment trial.

  Tanaka GH. Tanaka GH. Ophthalmology. 1996 Mar;103(3):346-7. doi: 10.1016/s0161-6420(96)80002-9. Ophthalmology. 1996. PMID: 8600400 Clinical Trial. No abstract available.
• [Optic neuritis. First manifestation of multiple sclerosis? Current diagnostic and therapeutic strategies].

  Kiefer G, Rieckmann P. Kiefer G, et al. Ophthalmologe. 2001 Mar;98(3):310-8. doi: 10.1007/s003470170169. Ophthalmologe. 2001. PMID: 11320823 Review. German. No abstract available.